Substance abuse and quality of life in chronic hepatitis C patients receiving antiviral treatment

E. Egmond; G. Oriolo; M. Cavero; K. Langohr; R. Solà; R. Navines; R. Martin-Santos

doi:10.1016/j.eurpsy.2016.01.240

Substance abuse and quality of life in chronic hepatitis C patients receiving antiviral treatment

Published online by Cambridge University Press: 23 March 2020

E. Egmond ,

G. Oriolo ,

M. Cavero ,

K. Langohr ,

R. Solà ,

R. Navines and

R. Martin-Santos

Show author details

E. Egmond*: Affiliation:
Hospital Clínic, Psychiatry and Psychology, Barcelona, Spain
G. Oriolo: Affiliation:
Hospital Clínic, Psychiatry and Psychology, Barcelona, Spain
M. Cavero: Affiliation:
Hospital Clínic, Psychiatry and Psychology, Barcelona, Spain
K. Langohr: Affiliation:
Polytecnic University of Barcelona, Statistics and Operation Research, Barcelona, Spain
R. Solà: Affiliation:
Hospital del Mar, Hepatology, Barcelona, Spain
R. Navines: Affiliation:
Hospital Clínic, Psychiatry and Psychology, Barcelona, Spain
R. Martin-Santos: Affiliation:
Hospital Clínic, Psychiatry and Psychology, Barcelona, Spain
*: * Corresponding author.

Article contents

Abstract
Introduction
Objectives
Methods
Results
Conclusions
Grant
Disclosure of interest

Abstract

Introduction

Chronic hepatitis C virus (HCV) is one of world's most important chronic infections. HCV can be treated using interferon-alpha (IFNα) and ribavirin (RBV). HCV, IFNα and RBV are known to impair mental and physical life quality. Many HCV-infected individuals have life-prevalence of substance use disorder (SUD).

Objectives

To study life quality (SF-36) in HCV patients with SUD history during antiviral treatment.

Methods

SF-36 questionnaire was assessed in 384 HCV patients at baseline, and at 4, 12, 24, and 48 weeks of treatment. ANCOVA models were used to study the association of SF-36 scores and potential risk factors at baseline. Risk factors from baseline scores over time were studied through linear mixed models, adjusting for baseline scores.

Results

At baseline, SUD men had worse mental (P = 0.03) and physical health (P = 0.022), and younger patients had worse social functioning (P = 0.011), and mental (P = 0.001) but better physical health (P < 0.001). Figs. 1 and 2 show the results of mental and physical life quality during treatment from baseline.

Conclusions

This study emphasizes the decrease in life quality in HCV patients with SUD before and during antiviral treatment.

Grant

Instituto de Carlos III-FIS: PSICOCIT-PI110/01827,EU “One way to make Europe”, Ministerio de Economia y Competitividad (MTM2012-38067-C02-01), and support of SGR/2014/1135.

Disclosure of interest

The authors have not supplied their declaration of competing interest.